In previous studies, syngeneic colon cancers responding to anti-PD1, CTLA4, or combination therapy displayed increases in CD8+ and GZB+ CD8+ cells and decreases in F4/80 myeloid cells [15, 16]. Here, CTLA4 is linked to malignant colon neoplasm.